Director Nelsen Robert buys 3,030,300 shares of PRME at $3.30 (+94.7% to holdings); co-clustered buy pattern by 3 other insiders in 14 days.
Director Robert Nelsen purchased 3,030,300 shares of Prime Medicine at $3.30 on 2025-08-01, adding $10.0M in value and increasing his holdings by 94.7% from 3,200,000 shares to 6,230,300 shares. The purchase coincides with a cluster of 3 other insiders also buying within the past 14 days, suggesting coordinated confidence in near-term fundamentals. Nelsen's cross-ticker track record shows 4 prior buys with an average 90-day return of 56.4% and a 100% win rate; however, his single prior PRME purchase on 2024-02-15 achieved only 8.2% over 90 days, indicating less favorable outcomes at this specific ticker. Against headwinds of a $-51.9M net loss in the most recent full fiscal year and a current price of $4.04 that is 28.0% below the 52-week high of $5.61, this large-size buy by an insider with a strong historical record warrants investor attention to the company's clinical or operational inflection points that may underpin the conviction.